Alliqua BioMedical, Inc. (ALQA) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Alliqua BioMedical, Inc. (NASDAQ:ALQA) from a sell rating to a hold rating in a report issued on Tuesday.

According to Zacks, “Alliqua, Inc. is a biomedical company. The company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies. Its technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers. The company’s product includes SilverSeal(R) a hydrogel wound dressing with silver coated fibers and Hydress(R) an over-the-counter hydrogel wound dressing. It serves the healthcare industry including wound healing, medical diagnostics and cosmeceuticals. Alliqua, Inc. is headquartered in Langhorne, Pennsylvania. “

Separately, HC Wainwright reiterated a buy rating on shares of Alliqua BioMedical in a research note on Friday, October 7th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $2.42.

Analyst Recommendations for Alliqua BioMedical (NASDAQ:ALQA)

Alliqua BioMedical (NASDAQ:ALQA) traded up 5.388% on Tuesday, reaching $0.665. The company had a trading volume of 1,216,362 shares. Alliqua BioMedical has a 12-month low of $0.57 and a 12-month high of $2.15. The stock’s market capitalization is $19.73 million. The stock’s 50-day moving average price is $0.64 and its 200-day moving average price is $0.88.

ILLEGAL ACTIVITY WARNING: This story was first published by Sports Perspectives and is the propert of of Sports Perspectives. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark laws. The correct version of this story can be viewed at

Several large investors have recently added to or reduced their stakes in ALQA. Suffolk Capital Management LLC raised its stake in Alliqua BioMedical by 4.8% in the third quarter. Suffolk Capital Management LLC now owns 1,264,101 shares of the company’s stock valued at $1,011,000 after buying an additional 57,974 shares in the last quarter. US Bancorp DE raised its stake in Alliqua BioMedical by 29.8% in the second quarter. US Bancorp DE now owns 181,732 shares of the company’s stock valued at $204,000 after buying an additional 41,732 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Alliqua BioMedical by 1.1% in the second quarter. Vanguard Group Inc. now owns 524,296 shares of the company’s stock valued at $587,000 after buying an additional 5,780 shares in the last quarter. Institutional investors own 29.84% of the company’s stock.

Alliqua BioMedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

5 Day Chart for NASDAQ:ALQA

Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply